Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Impact of Statins on Multiple Myeloma

J Clin Oncol; ePub 2016 Sep 19; Sanfilippo, et al

Publish date:: September 28, 2016

Statins were linked with reduced mortality risk in a cohort study involving nearly 5,000 US veterans with multiple myeloma.

Investigators looked at data of participants who were diagnosed with the disorder between 1999 and 2013. Among the results:

• Nearly 2,300 received statin therapy.

• Statin use was linked with a 21% decrease in all-cause mortality, and a 24% decrease in disease-specific mortality.

• Statin use was also linked with a 31% decreased risk of developing a skeletal-related event.

Citation: Sanfilippo K, Keller J, Luo S, et al. Statins are associated with reduced mortality in multiple myeloma. [Published online ahead of print September 19, 2016]. J Clin Oncol. doi:10.1200/JCO.2016.68.3482.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,